Individualized Faricimab Dosing up to Every 16 Weeks Maintains Robust Anatomic and Vision Outcomes Through 2 Years in nAMD
home / rapid-readouts / individualized-faricimab-dosing-up-to-every-16-weeks-maintains-robust-anatomic-and-vision
Dr Varun Chaudhary shares insights from his presentation at the 2023 ARVO annual meeting, highlighting key findings on personalized treatment interval dosing using faricimab.
EP. 2: Key Retreatment Decisions in the Clinical Trials for Faricimab in nAMD
July 21st 2023Dr Varun Chaudhary presents the retreatment decisions during the treat-and-extend phase of the TENAYA and LUCERNE clinical trials in neovascular AMD, focusing on the percentage of patients who maintained, extended, or reduced their treatment interval based on visual and anatomic criteria.
